1. Scrip
  2. >>Business

Pfizer Is Ready To File Vaccine, With More Good News On Over-65s Efficacy

94% Efficacy In Key Older Group

 
• By Andrew McConaghie

Pfizer is moving swiftly towards an emergency use approval filing, with Moderna not far behind.  

NEW YORK CITY - MAY 2015: Metal plate logo of Pfizer in his headquarters building. Pfizer is an American multinational pharmaceutical corporation, one of the world's largest pharmaceutical companies.
Pfizer and BioNTech will file for an Emergency Use Authorization 'within days' - with Moderna not far behind.

Pfizer and BioNTech have completed the Phase III study of their COVID-19 vaccine, and have declared themselves just “days away” from filing final safety and efficacy data with regulators around the world.

The companies announced their first interim analysis from its Phase III trial of mRNA-based vaccine candidate BNT162b2 on 9 November,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.